Eli Lilly 향후 성장

Future 기준 점검 5/6

Eli Lilly (는) 각각 연간 23% 및 14.7% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 22.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 60.3% 로 예상됩니다.

핵심 정보

23.0%

이익 성장률

22.33%

EPS 성장률

Pharmaceuticals 이익 성장	14.4%
매출 성장률	14.7%
향후 자기자본이익률	60.30%
애널리스트 커버리지	Good
마지막 업데이트	23 Dec 2025

최근 향후 성장 업데이트

Eli Lilly and Company Just Missed EPS By 26%: Here's What Analysts Think Will Happen Next

May 05

Recent updates

Eli Lilly: Mr. Market Finally Woke Up, But I'm Not Out Yet (Rating Downgrade)

Dec 24

Investors Appear Satisfied With Eli Lilly and Company's (NYSE:LLY) Prospects As Shares Rocket 30%

Nov 25

Eli Lilly (NYSE:LLY) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Nov 07

Eli Lilly's Future Growth Driven by Tirzepatide and Favorable Market Conditions

Sep 19Catalysts Mounjaro/Zepbound: Lilly’s tirzepatide franchise is the engine of growth. Mounjaro (for type 2 diabetes) and Zepbound (obesity) each grew rapidly in 2024.

Eli Lilly and Company Just Missed EPS By 26%: Here's What Analysts Think Will Happen Next

May 05

이익 및 매출 성장 예측

NYSE:LLY - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2027	89,458	34,933	25,479	32,481	25
12/31/2026	76,501	28,195	17,478	25,815	29
12/31/2025	63,578	20,399	11,215	19,156	25
9/30/2025	59,420	18,412	7,038	16,062	N/A
6/30/2025	53,258	13,800	551	10,938	N/A
3/31/2025	49,003	11,106	-668	9,318	N/A
12/31/2024	45,043	10,590	1,016	8,818	N/A
9/30/2024	40,863	8,370	-2,275	6,032	N/A
6/30/2024	38,923	7,342	-2,024	4,510	N/A
3/31/2024	35,932	6,138	-2,292	3,676	N/A
12/31/2023	34,124	5,240	-1,548	4,240	N/A
9/30/2023	32,073	4,988	1,469	6,215	N/A
6/30/2023	29,516	6,498	3,307	6,242	N/A
3/31/2023	27,691	5,687	3,881	6,793	N/A
12/31/2022	28,541	6,245	4,696	7,586	N/A
9/30/2022	29,240	6,033	5,404	8,080	N/A
6/30/2022	29,071	5,692	4,950	7,494	N/A
3/31/2022	29,323	6,129	5,824	8,086	N/A
12/31/2021	28,318	5,582	5,604	7,366	N/A
9/30/2021	27,759	5,972	4,621	6,919	N/A
6/30/2021	26,726	6,071	4,837	7,095	N/A
3/31/2021	25,486	6,093	5,565	7,815	N/A
12/31/2020	24,540	6,194	4,471	6,500	N/A
9/30/2020	23,214	5,573	5,112	6,648	N/A
6/30/2020	22,950	5,618	4,890	6,352	N/A
3/31/2020	23,087	5,533	3,684	4,908	N/A
12/31/2019	22,320	4,638	3,483	4,837	N/A
9/30/2019	21,843	4,264	2,671	4,322	N/A
6/30/2019	21,673	4,103	N/A	4,933	N/A
3/31/2019	21,622	2,545	N/A	5,399	N/A
12/31/2018	21,493	3,151	N/A	5,525	N/A
9/30/2018	22,016	372	N/A	5,819	N/A
6/30/2018	22,368	-166	N/A	5,579	N/A
3/31/2018	22,607	1,074	N/A	5,712	N/A
12/31/2017	19,974	-86	N/A	5,616	N/A
9/30/2017	22,471	2,225	N/A	5,879	N/A
6/30/2017	22,005	2,447	N/A	5,659	N/A
3/31/2017	21,585	2,187	N/A	5,410	N/A
12/31/2016	21,222	2,738	N/A	4,851	N/A
9/30/2016	20,837	2,444	N/A	3,841	N/A
6/30/2016	20,605	2,466	N/A	3,284	N/A
3/31/2016	20,179	2,319	N/A	2,830	N/A
12/31/2015	19,959	2,408	N/A	2,965	N/A
9/30/2015	19,704	2,359	N/A	3,318	N/A
6/30/2015	19,620	2,059	N/A	3,905	N/A
3/31/2015	19,577	2,192	N/A	4,010	N/A
12/31/2014	19,616	2,391	N/A	4,458	N/A

애널리스트 향후 성장 전망

수입 대 저축률: LLY 의 연간 예상 수익 증가율(23%)이 saving rate(3.3%)보다 높습니다.

수익 vs 시장: LLY 의 연간 수익(23%)이 US 시장(16.2%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 수익: LLY 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: LLY 의 수익(연간 14.7%)이 US 시장(연간 10.7%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: LLY 의 수익(연간 14.7%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: LLY의 자본 수익률은 3년 후 60.3%로 매우 높을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/12/24 22:38
종가	2025/12/24 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Eli Lilly and Company는 53명의 분석가가 다루고 있습니다. 이 중 29명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
David Toung	Argus Research Company
Luisa Hector	Berenberg
Kerry Holford	Berenberg

Eli Lilly 향후 성장

Future 기준 점검 5/6

핵심 정보

최근 향후 성장 업데이트

Price target increased by 7.4% to US$1,007

Price target increased by 7.8% to US$993

Eli Lilly and Company Raises Earnings Guidance for the Year 2025

Eli Lilly and Company Raises Earning Guidance for the Year 2025

Eli Lilly and Company Just Missed EPS By 26%: Here's What Analysts Think Will Happen Next

Eli Lilly and Company Reaffirms Earnings Guidance for the Year 2025

Recent updates

Eli Lilly: Mr. Market Finally Woke Up, But I'm Not Out Yet (Rating Downgrade)

Eli Lilly and Company Announces Oral GLP-1 Orforglipron

Eli Lilly and Company Announces Positive Topline Results from the ATTAIN-MAINTAIN trial

Eli Lilly and Company Announces Updated Data for Lilly's Inluriyo™ (Imlunestrant) Reinforce Efficacy Results as Monotherapy and in Combination with Verzenio® (Abemaciclib) in Er+, Her2- Advanced Breast Cancer

Dividend of US$1.73 announced

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 TRIUMPH-4 Clinical Trial

Insufficient new directors

Eli Lilly and Company Announces Results from the Phase 3 Bruin CLL-313 Clinical Trial of Jaypirca (Pirtobrutinib)

Now 20% undervalued

Eli Lilly and Company Announces U.S. Food and Drug Administration Approves Expanded Indication for Lilly's Jaypirca (Pirtobrutinib, 100 Mg & 50 Mg Tablets)

Wisner Baum Unleashes Rico Against Takeda Pharmaceuticals and Eli Lilly

Investors Appear Satisfied With Eli Lilly and Company's (NYSE:LLY) Prospects As Shares Rocket 30%

Eli Lilly and Company to Present Data from Two Positive Phase 3 Studies of Jaypirca (Pirtobrutinib) in Chronic Lymphocytic Leukemia at the 2025 American Society of Hematology Annual Meeting

Eli Lilly and Company Announces Appointment of Carolyn R. Bertozzi, Ph.D as New Board Member and Member of Science and Technology Committee and the Ethics and Compliance Committee, Effective December 8, 2025

Price target increased by 7.4% to US$1,007

Price target increased by 7.8% to US$993

Eli Lilly (NYSE:LLY) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Eli Lilly and Company Announces Management Appointments

Eli Lilly and Company Announces Positive Results from A Phase 2 Trial Evaluating the Safety and Efficacy of Eloralintide

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Second quarter dividend of US$1.50 announced

Eli Lilly and Company Raises Earnings Guidance for the Year 2025

Lilly's Omvoh (mirikizumab-mrkz) Approves by U.S. FDA as a Single-Injection Maintenance Regimen in Adults with Ulcerative Colitis

Eli Lilly and Company's Omvoh Demonstrates Early and Sustainable Improvement in Bowel Intention Outcomes for Patients with Ulcerative Colitis

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Adverum Biotechnologies, Inc. (NasdaqCM:ADVM) for $80.2 million.

Eli Lilly and Company Announces Results from the Primary Overall Survival Analysis of the Phase 3 Monarche Trial

Eli Lilly and Company to Report Q3, 2025 Results on Oct 30, 2025

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 Trials

Eli Lilly and Company Appoints Peter Marks as New Head of Infectious Disease and Senior VP of Molecule Discovery

Eli Lilly and Company's Omvoh (mirikizumab-mrkz) Is the First and Only Interleukin-23p19 (IL-23p19) to Help Patients with Moderately Active Ulcerative Colitis Achieve Sured, Long-Term Outcomes Through Four Years

Investor sentiment improves as stock rises 16%

Eli Lilly and Company Announces U.S. Food and Drug Administration Approves Inluriyo (imlunestrant) for Adults with ER+, HER2, ESR1-Mutated Advanced or Metastatic Breast Cancer

Eli Lilly's Future Growth Driven by Tirzepatide and Favorable Market Conditions

Eli Lilly and Company Announces Detailed Results from Surpass-PEDS, the First Phase 3 Trial to Evaluate the Safety and Efficacy of Mounjaro

Eli Lilly and Company Announces Positive Topline Results from ACHIEVE-3

Eli Lilly and Company Launches TuneLab Platform to Give Biotechnology Companies Access to AI-Enabled Drug Discovery Models Built Through over $1 Billion in Research Investment

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 BRUIN CLL-313 Clinical Trial of Jaypirca

Eli Lilly and Company Receives U.S. FDA's Breakthrough Therapy Designation for the Treatment of Certain Newly Diagnosed KRAS G12C-Mutant Lung Cancer

Eli Lilly and Company Announces Positive Topline Results from the Primary Overall Survival (OS) Analysis of the Phase 3 MonarchE Trial

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 Attain-2 Trial

Eli Lilly and Company Announces Retirement of Anne White as Executive Vice President and President Lilly Neuroscience, Effective from December 31, 2025

Chairman recently bought US$1.1m worth of stock

Ken Paxton Files Lawsuit in State Court Against Eli Lilly and Co

Chairman recently bought US$1.1m worth of stock

Chairman recently bought US$1.1m worth of stock

New major risk - Earnings quality

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of US$1.50 per share

Eli Lilly and Company Raises Earning Guidance for the Year 2025

Eli Lilly and Company Announces Topline Results from SURPASS-CVOT

Eli Lilly and Company Announces Results from the Long-Term Extension (LTE) of the Phase 3 Trailblazer-Alz 2 Study

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 BRUIN CLL-314 Clinical Trial of Jaypirca

Eli Lilly and Company Receives Positive Opinion from the Committee for Medicinal Products for Human Use (CHMP) in Early Symptomatic Alzheimer's Disease

Eli Lilly and Company to Report Q2, 2025 Results on Aug 07, 2025

Eli Lilly and Company Announces FDA Approves Updated Label for Lilly's Kisunla (donanemab-azbt) with New Dosing in Early Symptomatic Alzheimer's Disease

First quarter dividend of US$1.50 announced

Eli Lilly and Company Declares Dividend for the Third Quarter of 2025, Payable on September 10, 2025

Eli Lilly and Company Announces Detailed Results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 Clinical Trials Evaluating the Safety and Efficacy of Investigational Once-Weekly Insulin Efsitora Alfa

Eli Lilly and Company Announces Detailed Results from ACHIEVE-1, a Phase 3 Trial Evaluating the Safety and Efficacy of Orforglipron Compared to Placebo in Adults with Type 2 Diabetes and Inadequate Glycemic Control with Diet and Exercise Alone

Ninth Circuit Affirms Actos RICO Class Action Certification Against Takeda and Eli Lilly

Lilly to Offer All Approve Doses of Zepbound (Tirzepatide) Single-Dose Vials Through LillyDirect Self Pay Pharmacy Solutions

Eli Lilly Reportedly Nears $1.3 Billion Deal for Verve Therapeutics

Eli Lilly and Company Presents First Clinical Data for Its Investigational, Next-Generation Fra Targeting Adc in Platinum-Resistant Ovarian Cancer At the 2025 Asco Annual Meeting

Eli Lilly and Company (NYSE:LLY) agreed to acquire SiteOne Therapeutics, Inc. for $1 billion.

Eli Lilly and Company Announces Details of Presentation at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Eli Lilly and Company Receives Marketing Authorization in Australia for the Treatment of Early Symptomatic Alzheimer's Disease

Eli Lilly and Company Announces Zepbound (Tirzepatide) Showed Superior Weight Loss over Wegovy (Semaglutide) in Complete Surmount-5 Results Published in the New England Journal of Medicine

First quarter dividend of US$1.50 announced

Eli Lilly and Company, Lilly Cardiometabolic Health and Lilly Usa, Llc Announces Executive Appointments